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ABSTRACT 
 
Lipid nanocapsules (LNCs) are semi-rigid spherical capsules with a triglyceride core that present a 
promising formulation option for the pulmonary delivery of drugs with poor aqueous solubility. 
Whilst the biodistribution of LNCs of different size has been studied following intravenous 
administration, the fate of LNCs following pulmonary delivery has not been reported. We 
investigated quantitatively whether lung inflammation affects the clearance of 50 nm lipid 
nanocapsules, or is exacerbated by their pulmonary administration. Studies were conducted in 
mice with lipopolysaccharide-induced lung inflammation compared to healthy controls. Particle 
deposition and nanocapsule clearance kinetics were measured by single photon emission 
computed tomography/computed tomography (SPECT/CT) imaging over 48 h. A significantly lower 
lung dose of 111In-LNC50 was achieved in the lipopolysaccharide (LPS)-treated animals compared 
with healthy controls (p < 0.001). When normalised to the delivered lung dose, the clearance 
kinetics of 111In-LNC50 from the lungs fit a first order model with an elimination half-life of 10.5 ± 
0.9 h (R2 = 0.995) and 10.6 ± 0.3 h (R2 = 1.000) for healthy and inflamed lungs respectively (n = 3). 
In contrast, 111In-diethylene triamine pentaacetic acid (DTPA), a small hydrophilic molecule, was 
cleared rapidly from the lungs with the majority of the dose absorbed within 20 min of 
administration. Biodistribution to lungs, stomach-intestine, liver, trachea-throat and blood at the 
end of the imaging period was unaltered by lung inflammation. This study demonstrated that lung 
clearance and whole body distribution of lipid nanocapsules were unaffected by the presence of 
acute lung inflammation. 
 
Keywords (maximum of 6): Lipid nanocapsules; pulmonary drug delivery; biodistribution; 
SPECT/CT; lung clearance kinetics; inflammation.  
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1. Introduction  
A large proportion of compounds under development for inhaled therapy of respiratory 
disease have poor aqueous solubility or a short half-life in the lungs [1–3]. The aerosol 
administration of relatively insoluble compounds can result in a dose-dependent, solubility-
dependent accumulation of particulate drug material in the lungs [4]. The long-term implications 
of macrophage responses to drugs of this nature is not completely understood and can be a 
barrier to the progress of such compounds to clinical development [5]. There are a variety of 
formulation strategies that may help circumvent the issues of insoluble particle accumulation in 
the airways, including the loading of agents in lipid nanocapsules [6].  
Lipid nanocapsules are core-shell nanoparticle systems with an oily core comprised of 
triglycerides, a lipophilic material capable of dissolving compounds with poor aqueous solubility 
(e.g. the anti-cancer agents, paclitaxel and tretinoin) [7–10]. The core is surrounded by a semi-rigid 
shell typically consisting of phosphotidylcholines and surfactants [11]. Lipid nanocapsules can be 
manufactured on an industrial scale, exhibit long storage shelf-lives in suspension, demonstrate a 
high stability during nebulisation [9,12] and achieve constant, reproducible drug release profiles 
[13,14]. Furthermore, lipid nanocapsules have shown an excellent in vivo biocompatibility profile 
following single pulmonary administration across a range of therapeutically relevant doses [15,16] 
and are not associated with acute adverse macrophage responses [15].   
While whole body distribution studies have been performed with lipid nanocapsules of 
different sizes following intravenous (i.v.) administration [17], the clearance and biodistribution of 
lipid nanocapsules following administration to the lungs has not been reported. Since lipid 
nanocapsules may be developed as drug carrier systems for the treatment of lung conditions 
which are likely to be accompanied by inflammation (e.g. respiratory infections, asthma or chronic 
obstructive pulmonary disease), it is important to study their biodistribution and clearance kinetics 
in the inflamed lung as well as healthy controls. Alternatively, if inhaled lipid nanocapsules were 
used as treatment vehicles in clinical scenarios where little or no lung inflammation was present 
(e.g. pulmonary hypertension or systemic delivery of drugs), it would be of relevance to 
understand whether the inhaled therapy would be affected by secondary respiratory tract 
infections [18,19]. Therefore, the aim of this study was to investigate the kinetics of lipid 
nanocapsule lung clearance and whole body distribution following administration to the mouse 
lung in the presence and absence of bacterial lipopolysaccharide (LPS), an endotoxin from 
Escherichia coli that induces acute lung inflammation [20–23]. It was hypothesised that (i) lipid 
nanocapsule administration to the inflamed lung would result in a modified clearance rate of the 
nanoformulation from the lungs compared to healthy control animals, but (ii) due to their high 
biocompatibility, lipid nanocapsules would not exacerbate the inflammation caused by the LPS 
pre-treatment. 
 
2. Materials and Methods 
2.1. Lipid nanocapsule manufacture and characterisation 
Lipid nanocapsules were manufactured using the phase-inversion temperature method [11]. 
Briefly, lipid nanocapsules were prepared by generating a coarse emulsion of 17% w/w Labrafac® 
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Lipophile WL1349 (Gattefosse, Saint-Priest, France), 17.5% w/w Solutol® HS15 (BASF, 
Ludwigshafen, Germany), and 1.75% w/w Lipoid® S75-3 (Lipoid GmbH, Ludwigshafen, Germany) in 
a 3% w/w sodium chloride (NaClaq) solution. The emulsion was subjected to repeated heating and 
cooling cycles (85°-60°-85°-60°-85°C) before cooling to 72°C, quenching in a 2-fold volume of ice 
water and stirring at room temperature for 5-10 min. The nanocapsule suspension was filtered 
(0.45 µm syringe filter) and excess stabiliser (Solutol® HS15) was removed by dialysis (72 h) against 
water containing BioBeads® (BioRad, Hertfordshire, UK). Suspensions were concentrated prior to 
administration using ultrafiltration centrifuge tubes (Millipore Ltd., Hertfordshire, UK; 100 kDa 
MWCO). Residual Solutol® HS 15 content was < 0.5 mg/mL. Particle size and zeta potential were 
measured using a Zetasizer Nano ZS (Malvern, Worcestershire, UK). Nanocapsules were diluted 
1:50 in purified water or saline and measurements taken at 25°C for quality control, at a scattering 
angle of 173°, using a viscosity value of water (0.8872 cP) for the dispersant. While all nanocapsule 
suspensions were size-stable for over four weeks when stored in purified water at 4°C [16], fresh 
batches were prepared for each in vivo experiment and used within 7 days of manufacture. Zeta 
potential measurements were performed at 25°C at a concentration of 20 μg/mL with all 
suspensions diluted in 6.3 mM NaClaq. Suspension concentration was determined gravimetrically. 
 
2.2. Nanocapsule radiolabeling with 111indium-chloride and stability studies 
To incorporate a radiolabel chelator into the shell of the nanocapsule systems (radiolabeled 
formulation have been abbreviated as 111In-LNC50), 0.1% w/w 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-diethylenetriaminepentaacetic acid (DMPE-DTPA) (Avanti Polar Lipids 
Inc, Alabama, USA) was added to the components during the coarse emulsion step and the 
nanocapsules were prepared as described above. Suspensions were diluted to 12 mg/mL with 0.1 
M ammonium acetate (pH 6.6) [24]. 111Indium-chloride (Mallinckrodt Medical Inc, Petten, The 
Netherlands), ~50 MBq (111InCl3, half-life 2.83 days), was dissolved in 0.5 M ammonium acetate 
(pH 5.0) and mixed with LNC50-DMPE-DTPA at a ratio of 1:2 v/v. The mixture was incubated at 
37°C for 45 min under gentle shaking. Radiolabeling efficiency was measured by quantifying the 
radioactivity in the ultrafiltrate of the washing solution and washed particle residue after three 
cycles of washing using spin filtration with Amicon ultrafiltration centrifuge tubes (Millipore Ltd., 
Hertfordshire, UK; 30 kDa MWCO). 
To assess the radiolabel stability in a biological environment, 5 µL of 111In-LNC50 
nanosuspensions (0.1-0.2 mg/mL) were added to 495 µL foetal bovine serum (FBS, Gibco (R), Life 
Technologies, UK) or phosphate buffered saline (PBS, pH 7.4; Oxiod Ltd, Basingstoke, UK) and 
incubated at 37°C with gentle shaking. At 24 and 48 h, 111In-LNC50 were collected and centrifuged 
for 3 min at 10,000 g using ultrafiltration centrifuge tubes (30 kDa MWCO). The free 111In content 
in the ultrafiltrate and particle residue was assayed using a Capintec/Mucha gamma counter (1282 
Compugamma Laboratory Gamma Counter, LKB Wallac, Australia). For control experiments, 
diethylene triamine pentaacetic acid (DTPA) (Sigma-Aldrich, Dorset, UK) was dissolved in 0.5 M 
ammonium acetate (pH 6.6) to prepare a 1 mg/mL solution. 111InCl3 (37 MBq) was mixed with 0.5 
M ammonium acetate (pH 6.6) at a 1:1 v/v ratio resulting in a final pH of 5.0. The 111In solution (40 
µL) was mixed with the DTPA solution (20 µL) and incubated at 37°C for 90 min to obtain 111In-
DTPA. 
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2.3. Induction of inflammation and administration of lipid nanocapsules 
All procedures were conducted in accordance with the United Kingdom Animal Scientific 
Procedures Act, 1986 and were approved by the ethics committee of Kings College, London. In 
vivo experiments were performed with male BALB/C mice (6-8 weeks of age; Harlan, UK). Mice 
were housed in rooms maintained at a constant temperature (21 ± 2°C) and humidity (55 ± 15%) 
with a 12 h light-dark cycle. Animals had food and water available ad libitum and were allowed a 1 
week acclimatisation period before use. 
Animals were separated into six cohorts (n = 3-7) and were anaesthetised with isoflurane 3-
5% v/v in O2 at a flow rate of 1.0 L/min before intranasal (i.n.) administration of 25 µL of LPS 
(Sigma-Aldrich, Dorset, UK; 1 or 10 µg/mouse) or 0.9% saline (SAL; vehicle control for healthy 
animals). At t = 0 h, 25 µL of lipid nanocapsule suspension (175 µg/mouse) or saline vehicle control 
was administered using an oropharyngeal aspiration (o.a.) procedure [25]. Aspiration was 
confirmed visually.  
 
2.4. Measurement of inflammation 
Mice were killed humanely at 24 h with an intraperitoneal (i.p.) injection (0.5 mL) of 25% 
urethane. Lungs were lavaged with 3 x 0.5 mL of sterile 0.9% saline, which were combined and 
stored on ice. The lungs were removed and inflated with 10% formalin. Tissue histology was 
performed on three transverse sections cut through the left lung, dehydrated through ascending 
grades of ethanol and embedded in paraffin wax. Sections were stained with hematoxylin and 
eosin (H&E) stain to assess general morphology [26]. 
The total cell count in bronchoalveolar lavage (BAL) was determined immediately following 
lavage by mixing 50 µL BAL fluid with 50 µL Türk solution (Merck Chemicals, Darmstadt, Germany) 
and counting live cells using a haemocytometer. For differential cell counts, cytospin slides were 
prepared using 100 µL of BAL fluid spun at 1000 RCF for 1 minute. Slides were dried before 
differential staining (Reastain Quick-Diff Kit; Reagena Ltd, Toivala, Finland) and mounting (DPX; 
Fisher Scientific, Leicestershire, UK). A total of 100 cells were evaluated to determine the 
proportion of neutrophils, eosinophils and macrophages using standard morphological criteria. No 
eosinophils were detected in any of the samples. Total protein levels in BAL were quantified using 
a Quick Start™ Bradford Protein Assay (Bio-Rad, Hemel Hempstead, UK) according to 
manufacturer’s instructions.  
 
2.5. Single photon emission computed tomography/computed tomography (SPECT/CT) imaging  
To measure clearance of lipid nanocapsules from healthy versus inflamed lungs, animals 
were grouped into four cohorts (n = 3). Intranasal pre-treatment with LPS (1 µg) or saline vehicle 
was performed as described above, followed 24 h later by o.a. administration of 111In-LNC50 
suspensions (125 μg solids/mouse, 2.5-3.0 MBq) or 111In-DTPA (2.5-3.0 MBq) solutions. SPECT/CT 
scans were acquired for the whole body with mice placed in the prone position and a pressure 
transducer placed under the abdomen for respiratory monitoring. Scans were acquired at 0.25, 3, 
24 and 48 h after 111In- nanocapsule administration using a NanoSPECT/CT PLUS preclinical animal 
scanner (Mediso, Hungary). Mice dosed with 111In-DTPA in PBS were treated as above with the 
exception of additional images collected at t = 0, 11, 23 and 35 min to capture the faster rate of 
clearance from the lungs (n = 1). CT images were obtained using a 55 kVP X-ray source, 500 ms 
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exposure time in 240 projections, a pitch of 1 and an acquisition time of 8 minutes. CT was imaged 
prior to SPECT, which was acquired using an exposure time of 1200 s, obtained over 60 projections 
and equipped with a 4-head scanner each with nine 1 mm pinhole apertures in helical scan mode 
with a total acquisition time of 35 min. CT images were reconstructed in a 352 × 352 matrix using 
proprietary Bioscan InVivSCope (Bioscan, USA) software, whereas SPECT images were 
reconstructed in a 256 × 256 matrix using HiSPECT (ScivisGmbH, Bioscan). Images were fused and 
analysed using InVivoScope (Version 1.44, Bioscan) for intensity counts. 3D regions of interests 
(ROI's) were created for desired organs at each time point using InviCRO 3D and the counts decay 
corrected and compared to the total delivered dose for each mouse to assess biodistribution and 
clearance. Following the final scan, mice were culled by cervical dislocation, tissue samples were 
excised, and radioactivity was counted in a gamma counter (LKB Wallac, Finland). The radiotracer 
activity in the samples was corrected for background decay time. 
 
2.6. Organ distribution of lipid nanocapsules 
A parallel set of animals were grouped into the same four cohorts (n = 3) to examine organ 
biodistribution. Inflammation was induced and 111In-L C50 or 111In-DTPA were administered as 
described above. Mice were humanely killed with an i.p. injection of 0.5 mL urethane (25%) at 
0.25, 3, 24 or 48 h after 111In-LNC50 or 111In-DTPA administration. Lungs were lavaged with 3 x 0.5 
mL of sterile saline and a sample (200 µL) of BAL fluid was set aside whilst the remaining BAL was 
centrifuged for 20 min at 500 rpm to separate the supernatant from the cellular fraction. In 
addition, the throat, trachea, lungs, salivary glands, thymus, heart, stomach, intestines, liver, 
kidneys, spleen, bladder, faeces, muscle and blood were removed. Each sample was counted on a 
1282 Compugamma Counter (LKB Wallac, Finland), together with standards prepared in a 
corresponding matrix. Data was corrected for radioactive decay during the experimental period 
and expressed as a percentage of the original activity. 
 
2.7. Statistical analysis 
Statistical Package for Social Sciences (SPSS) software (version 20.0; SPSS Inc., IBM, UK) was 
used for all statistical analyses. Data was analysed for normality using the Shapiro–Wilk test. 
Chelation stability was performed by systematic comparison of group means using a paired two-
tailed Student’s t-test. BAL cell counts from nanocapsule - and saline-challenged mice were 
compared using one way ANOVA on log transformed data followed by a post-hoc Tukey test. 
Particle size, lung clearance rates and 3-D image analysis from SPECT/CT was performed using a 
two way repeated measures ANOVA comparison with a post-hoc Bonferroni test. p < 0.05 was 
considered significant. 
 
3. Results 
3.1. Particle size, radiolabeling efficiency and stability of nanosuspensions 
The lipid nanocapsules possessed a similar particle size, polydispersity index and surface 
charge to previously manufactured systems using similar conditions (Table 1) [11,15]. 
Incorporation of the chelator, DMPE-DTPA, into the shell of the nanocapsules resulted in 
marginally larger hydrodynamic diameters (p < 0.01) and an anionic surface charge (table 1) (p < 
0.01).  There was no significant change in the anionic surface charge between nanocapsules and 
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LNC50-DMPE-DTPA in 150 mM sodium chloride solution (p > 0.05). All systems were highly stable 
in suspension over a four week storage period (Supplementary Fig. S1). The surface charge of the 
labelled particles most probably arose as a consequence of the ionised carboxylic acid groups of 
DMPE-DTPA and it was suspected that this would probably be reduced once the 111InCl3 was 
attached to the DMPE-DTPA. As a consequence the negative surface charge was not considered to 
have a significant impact on the surface chemistry of the particles when compared to the 
unlabelled material.  
 
Table 1. Particle size and surface charge of lipid nanocapsules with and without DMPE-DTPA 
incorporation. Data represents mean ± standard deviation of the hydrodynamic diameter (Dh), 
polydispersity index (PDI) and zeta potential of three batches of nanosuspensions in purified water, 
physiological saline  (NaCl 150 mM) and a dilute saline solution (NaCl 6.3 mM) at 25°C. 
   
 Purified Water NaCl (150 mM) NaCl (6.3 mM) 
 Dh (nm) PDI ζ (mV) Dh (nm) PDI ζ (mV) Dh (nm) PDI ζ (mV) 
Lipid nanocapsules 
(LNC50) 
46.9 ± 
0.4 
0.1± 
0.01 
-7.7 ± 
1.2 
42.6 ± 
0.2 
0.05 ± 
0.01 
-2.6 ± 
0.4 
48.2 ± 
0.4 
0.05 ± 
0.01 
-4.7 ± 
0.9 
LNC50-DMPE-DTPA 50.7± 2.2 0.05 ± 
0.03 
-27.4 ± 
3.5 
46.7± 
1.3 
0.10 ± 
0.01 
-5.4 ± 
1.2 
52.7± 
1.4 
0.04 ± 
0.02 
-12.1 ± 
2.3 
 
The labelling efficiency of 111In- nanocapsules (111In-LNC50) was 91.2 ± 2.2 % (n = 5) when the 
filter binding of the label (6.8 ± 0.9 %) was accounted for and the 111In-LNC50 were shown to be 
completely absent from the unbound label. This was demonstrated by a 98.0 ± 2.8 % (n = 5) 
recovery of the label during the washing process and the absence of significant levels of 111In in 
the ultrafiltrate of suspensions following incubation in FBS and PBS (150 mM, pH 7.4) (n = 3; p > 
0.05). 
 
3.2. Lung inflammation 
LPS was used to induce airway neutrophilia to determine whether nanocapsule 
administration to inflamed lungs exacerbates the pre-existing inflammation. Administration of LPS 
(10 and 1 μg i.n.) was used to induce a robust acute inflammatory response in the mouse lung 
characterised by an increase in total BAL cell numbers and a significant increase in BAL neutrophils  
(Fig. 1B-C). The 10 μg dose represented a typical LPS model of neutrophilic inflammation and it 
was observed that LNC administration did not exacerbate the inflammation.  It was not possible to 
use the higher LPS dose in imaging studies, as animals with a moderate level of lung inflammation 
were susceptible to respiratory distress under the prolonged anaesthesia necessary for image 
acquisition.  Therefore, a 1 μg dose of LPS was used to induce a mild, but significant, inflammatory 
response which was also not influenced by LNC administration.  In all LPS-treated cohorts, the 
neutrophilic response was fully resolved by t = 72 h post-administration of LPS (data not shown).  
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Lipid nanocapsule treatment using an o.a. procedure did not induce acute inflammation in 
healthy lungs (Fig. 1B-D), thus confirming previous findings [15,16]. Histological analysis of lung 
tissue showed an accumulation of neutrophils in the lungs obtained from mice pre-treated with 
LPS (Fig. 2C-D) in comparison to mice with a saline pre-treatment (Fig. 2A-B). LPS-induced 
inflammation was characterised by peri- bronchial foci of neutrophils and fibrin, prominence of 
alveolar macrophages, and intra-alveolar haemorrhage. No significant differences in BAL total 
protein could be detected between the treatment groups (p > 0.05). BAL fluid cytokine analysis 
was not performed in this study, as we have previously published cytokine levels post-LNC 
administration [15]. 
 
 
 
 
Fig. 1. Assessment of inflammatory parameters in bronchoalveolar lavage (BAL). (A) dosing 
schedule, (B) total number of cells, (C) neutrophils and (D) total protein in BAL at t = 24 h into the 
dosing schedule. Columns represent mean ± SEM (n = 3-7). No significant difference between the 
(SAL)/SAL (saline control) and (SAL)/LNC50 (treatment) groups was observed. LPS pre-treatment 
increased inflammatory parameters compared with the respective saline control; * p < 0.05, ** p < 
0.01. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
9 
 
 
Fig. 2. Histopathology of lung tissue exposed to lipid nanocapsules following saline or LPS pre-
treatment. Representative images of lung tissue harvested at t = 48 h from the following treatment 
groups: A) (SAL)/SAL, B) (SAL)/ LNC50, C) (LPS)/SAL, or D) (LPS)/LNC50 (20× magnification; scale 
bar = 100 μm). 
 
3.3. Lung clearance and biodistribution using non-invasive longitudinal SPECT/CT imaging 
Four cohorts of animals (Fig. 3A) were used to investigate whether lung clearance and 
subsequent biodistribution of 111In-LNC50 was influenced by lung inflammation. The small, 
hydrophilic molecule, 111In-DTPA, was used as a control for ligand-radiolabel stability in the 
nanocapsules. As expected, 111In-DTPA lung clearance was extremely rapid, with a majority of the 
o.a. administered dose crossing the air-blood barrier within the first 25 min post-administration 
(Fig. 3B) and a majority of the signal accumulating in the kidneys and bladder [27,28], from where 
it was eliminated within 24 h (Fig. 3C-D). No detectable differences in 111In-DTPA lung clearance 
were observed between the healthy versus inflamed lung (Fig. 3C-D). SPECT/CT images of o.a.-
administered 111In-LNC50 revealed that lipid nanocapsules were cleared from the lungs over 48 h. 
Analysis of the signal in the mouth, trachea and lungs at the first image acquisition time showed 
that a lower lung dose (total activity/organ) was observed in the (LPS1µg)/
111In-LNC50-treated 
animals compared with saline (SAL)/111In-LNC50 treated animals. No qualitative differences in 
111In-LNC50 lung clearance were observed between the healthy versus inflamed lungs (Fig. 3E-F). 
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Fig. 3. Whole-body SPECT/CT images of 111In-DTPA or 111In-LNC50 following pre-treatment with LPS 
(1 µg) or saline (SAL). A) Dosing schedule. B) Rapid acquisition of a sequence of SPECT images of 
the mouse thorax at t = 5, 15, 25, and 35 min post 111In-DTPA administration (o.a.) was necessary 
to monitor the clearance of 111In-DTPA from the lungs. SPECT/CT images of the whole body were 
acquired over 24 h for (SAL)/111In-DTPA (C) and (LPS1µg)/
111In-DTPA (D) treatment groups, while 
(SAL)/111In-LNC50 (E) and (LPS1µg)/
111In-LNC50 (F) treatment groups were monitored from up to 48 
h. All activity has been decay corrected and compared against the first scan at 0.25 h (i.e. 15 min 
post o.a. administration) for each mouse. 
 
3-D image analysis was used to study the biodistribution of the radiolabelled systems semi-
quantitatively for 48 h post-administration. The lungs, intestines, bladder and liver, were chosen 
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as regions of interest for quantitative analysis (Fig. 4). The lung dose of the 111In-LNC50 was 
significantly higher at the first scan (0.25 h post-dosing) compared to 111In-DTPA (p < 0.001), 
because 111In-DTPA rapidly crossed the air-blood barrier rapidly into the systemic circulation and 
accumulated in the bladder (Fig. 3B, 4A, C). A statistically significant, lower lung dose (total 
activity/organ) was observed in the (LPS1µg)/
111In-LNC50 treated animals (35.08 ± 5.27%) at 0.25 h 
compared with (SAL)/111In-LNC50 treated animals (51.63 ± 3.29%) (Fig. 4A; p < 0.001). Analysis of 
the signal in the mouth, trachea and lungs at the first image acquisition time (t = 0.25 h) revealed 
that LPS-treated animals typically showed a lower lung and higher mouth signal distribution, 
whereas the pattern was reversed in healthy mice (Fig. 4E), which may indicate that animals with 
lung inflammation had a lower inspiratory capacity and did not aspirate liquid into the lungs to the 
same extent as their healthy counterparts. Notably, only 111In-LNC50- treated animals showed an 
accumulation of signal in the liver, peaking at t = 24 h, possibly indicating that a portion of the 
nanocapsule dose were able to traverse the air-blood barrier and enter the systemic circulation 
intact, whereby they encountered circulating phagocytic cells in the blood and were cleared to the 
liver [29,30].  
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Fig. 4.  Distribution of 111In-DTPA and 111In-LNC50 nanosuspensions administered by oral aspiration 
to mice with the healthy vs. inflamed lungs. The 111In signal per organ was measured by 3-D image 
analysis over 48 h and is reported as a percentage of the total signal count from the first acquired 
image (with correction for signal decay). Signal distribution is reported for the (A) lungs, (B) 
stomach-intestines, (C) bladder and (D) liver. Values represent the mean ± standard deviation from 
n = 3 animals in each cohort (n=2 for the (SAL)/111In-LNC50 group, due to exclusion of one mouse 
where the majority of the dose was ingested). (E) Signal distribution of 111In-LNC50 in various 
organs of individual animals in the first full SPECT/CT image (t = 0.25 h of the study schedule) is 
shown to evaluate whether the LPS model of inflammation affects the pulmonary dose following 
o.a. administration. (***) p < 0.001, statistically significant between (SAL)/111In-LNC50 vs. 
(LPS1µg)/
111In-LNC50. 
 
The lung clearance kinetics of 111In-DTPA and 111In-LNC50 suspensions were calculated from 
the imaging data after normalisation to the original lung dose. The clearance kinetics of 111In-
LNC50 from the lungs fit a first order model (Fig. 5) with an elimination half-life of 10.5 ± 0.9 h (R2 
= 0.9950) and 10.6 ± 0.3 h (R2 = 0.9996) for groups pre-treated with saline and LPS1µg, respectively 
(p > 0.05). 
 
Fig. 5. Lung clearance kinetics 
from SPECT/CT images for 111In-
DTPA and 111In-LNC50 in mice 
with healthy vs. inflamed lungs (n 
= 3). Values have been corrected 
for decay and normalised to the 
initially deposited lung dose for 
lung clearance. Curves for 111In-
LNC50 were fitted according to a 
one phase exponential decay 
model (Prism 5.0, Graphpad). p > 
0.05, (SAL)/111In-LNC50 vs. 
(LPS1µg)/
111In-LNC50. 
 
3.4. Lung clearance and biodistribution using terminal end-point studies 
Nanocapsule distribution and clearance from the lungs, was evaluated further using terminal 
end-point studies with the same dosing schedules as the imaging studies (Fig. 6A-H; 
Supplementary Information Fig. S2A-H). The biodistribution profiles from terminal end-point 
studies were very similar to the SPECT/CT profiles demonstrating that non-invasive, longitudinal 
imaging is a reliable and useful alternative methodology. Only minor differences between the two 
methods were observed. For instance, sequential SPECT scanning was better suited to assess the 
rapid clearance of compounds, such as 111In-DTPA from the lungs, compared to end-point studies. 
However, SPECT imaging was not able to detect the diluted radiolabel signals present in the 
bloodstream; for this application, blood sampling and γ-scintigraphy measurement was required.  
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The localisation of the radioactive signal within the lungs over time was assessed by lung 
lavage performed at t = 3 and 24 h per treatment group with the radioactivity measured in the 
total BAL (i.e. BAL fluid + cellular fraction) as well as the isolated BAL cellular fraction. The 
radioactivity recovered in the BAL generally reflected the lung clearance profiles of the respective 
systems. 111In-DTPA was observed primarily in the BAL fluid and was cleared within the first 25 min 
after dosing, while 111In-nanosuspensions remained in the total BAL fluid and cleared slowly.  
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Fig. 6. Biodistribution of 111In-DTPA and 111In-LNC50 nanosuspensions after delivery by oral 
aspiration to mice with healthy vs. inflamed lungs. The distribution of radioactivity is reported in 
isolated fluids/organs after animal sacrifice for A) total BAL, B) BAL cellular fraction, C) lungs, D) 
stomach-intestines, E) bladder, F) liver, G) blood and H) trachea-throat. Values have been corrected 
for decay and represent the mean ± standard deviation from n = 3 animals at each time point.  
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4. Discussion 
Lipid nanocapsules are promising drug carriers systems for compounds such as those with 
poor aqueous solubility (e.g. paclitaxel and trerinoin) [7,10,31,32] and compounds benefitting 
from an extended retention time in the lungs (e.g. iloprost) [33]. Some of these compounds may 
be used to treat conditions that are accompanied by lung inflammation (e.g. asthma, COPD, 
respiratory tract infections), while in other therapeutic scenarios lung inflammation may not be a 
feature (e.g. pulmonary hypertension, lung cancer, systemic delivery of drugs). For indications 
where lung inflammation is not a prominent feature, it is important to determine whether any 
secondary inflammation acquired during the therapy (e.g. a lung infection) will influence the 
pharmacokinetic profiles of the inhaled compound. For example, several important clinical studies 
have been carried out to investigate whether upper respiratory tract infections influenced the 
pharmacokinetic profiles of inhaled insulin formulations [18,19]. To date, there are no published 
studies investigating whether inhaled nanoparticle drug carriers will positively or negatively 
influence an existing lung inflammation or alternatively whether the inflamed lung will influence 
the clearance profile and resulting pharmacokinetics of inhaled nanomedicines.  Both are clinically 
relevant questions, which are addressed in the current study using lipid nanocapsules as an 
example of an advanced formulation strategy with real clinical potential. 
Similar to previously published reports [15,16], lipid nanocapsule administration to the 
healthy lung was well tolerated. Importantly, nanocapsule administration to a murine model of 
neutrophilic airway inflammation did not to exacerbate the pre-existing inflammatory condition.  
Contrary to the study hypothesis, lipid nanocapsule clearance kinetics was not influenced by a pre-
existing mild lung inflammation.  It would be interesting to see whether a threshold of severity of 
lung inflammation exists above which an effect might be seen. This might be accomplished more 
readily with terminal end-point studies or imaging methods with faster acquisition times, both of 
which would not require prolonged periods of anaesthesia and would be more compatible with 
disease models of a higher severity.   
Interestingly, nanocapsule lung clearance kinetics were more rapid than expected, with a 
half-life of ~10.5 h, in contrast to other nanocarriers reported in the literature, such as albumin 
nanoparticles (~200 nm; clearance half-life ~96 h) and albumin protein in solution (~4-6 nm) [34]. 
This profile indicates a moderate lung retention, which could be compatible with a once-a-day 
administration frequency and a sustained drug release profile over a 24 h period. Therapeutic 
applications for such a pharmacokinetic-modulating formulation include the treatment of 
pulmonary hypertension with inhaled iloprost (Ventavis®), which due to the short half-life of 
iloprost in the lung requires administration frequencies of 6-9 doses per day [35]. 
Both the imaging and terminal end-point biodistribution studies provided an indication of 
the fate of lipid nanocapsules following o.a. administration. In the lung, the nanocapsules 
remained primarily in the lung lining fluid avoiding phagocytosis by alveolar macrophages, a 
behaviour which was attributed to the pegylated (‘stealth’) surface chemistry and the small 
particle size, which reduce macrophage detection and phagocytosis [36–38], whilst promoting 
translocation across the air-blood barrier [29,30,39]. The increase in signal in the liver at t=24 h 
post-administration (absent in the 111In-DTPA groups) suggests that at least a fraction of the lung 
dose was able to cross the air-blood barrier and enter into the systemic circulation as intact 
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nanoparticles, accumulating subsequently in the liver [29,30]. Previous studies have shown that 
lipid nanocapsules are highly stable in biological fluids, such as cell culture media and gastric fluids 
[40,41]; although nanocapsule stability and drug release studies have yet to be performed in lung 
lining fluid or lung lining fluid mimetics. In vitro studies have also shown that lipid nanocapsules 
are able to traverse epithelial cell monolayers intact, possibly through transcytosis [42], however, 
this may not be the only mechanism by which nanocapsules are cleared from the lung in vivo. 
Mucociliary clearance and subsequent swallowing may have also cleared a fraction of the lung 
dose especially that delivered to the upper airways, bronchi and trachea.  When 111In-DTPA or 
111In-LNC50 were administered by o.a., it was impossible to quantify mucociliary clearance from 
the imaging and terminal end-point studies as there were high GI tract signal levels in the first 24 h 
resulting from the swallowed fraction of the dose (~60%) at the point of administration. However, 
by 24 h the ingested dose was eliminated and signal levels in the GI tract from 24-48 h were nearly 
undetectable, indicating that mucociliary clearance was not a major pathway for lipid nanocapsule 
removal from the lungs after 24 h. Interestingly, no systemic absorption of 111In-LNC50 
components from the GI-tract was observed in animals where the majority of the entered the GI-
tract instead of the lung (Supplementary Fig. S3A-E), which supports the observation that the liver 
accumulation measured in the current study resulted from the lung fraction, rather than the 
ingested fraction of the dose. 
 
5. Conclusions 
Few clinical trials and even fewer studies in animal models have investigated the effect of 
inflammation on the clearance of drugs or nanocarriers from the lungs. This study demonstrated 
that pulmonary delivery of lipid nanocapsules was well tolerated after a single dose and does not 
exacerbate an existing acute lung inflammation. Lipid nanocapsules exhibited clearance half-life of 
~10.5 h regardless of whether the lung was healthy or inflamed. The safety and lung retention 
verifies that the nanocapsules are a promising option for modulating the pharmacokinetics of 
drugs delivered to the lungs. This study provides clinically relevant information that will be useful 
for guiding the design of future drug formulation studies with lipid nanocapsules as a drug carrier 
for a wide range of applications. 
 
Acknowledgments 
 
The authors would like to thank the UK Medical Research Council for funding this study 
(G0900953). The Centre of Excellence in Medical Engineering funded by the Wellcome Trust and 
EPSRC under grant number WT 088641/Z/09/Z for use of the scanning equipment. 
 
References 
[1] J.A. Tolman, R.O. Williams, Advances in the pulmonary delivery of poorly water-soluble 
drugs: influence of solubilization on pharmacokinetic properties, Drug Dev. Ind. Pharm. 36 
(2010) 1–30. doi:10.3109/03639040903092319. 
[2] A.E. Cooper, D. Ferguson, K. Grime, Optimisation of DMPK by the Inhaled Route: Challenges 
and Approaches, Curr. Drug Metab. 13 (2012) 457–473. doi:10.2174/138920012800166571. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
17 
 
[3] A.J. Hickey, Controlled delivery of inhaled therapeutic agents, J. Control. Release. 190 (2014) 
182–188. doi:10.1016/j.jconrel.2014.05.058. 
[4] R.M. Jones, N. Neef, Interpretation and prediction of inhaled drug particle accumulation in 
the lung and its associated toxicity, Xenobiotica. 42 (2012) 86–93. 
doi:10.3109/00498254.2011.632827. 
[5] B. Forbes, R. O’Lone, P.P. Allen, A. Cahn, C. Clarke, M. Collinge, et al., Challenges for inhaled 
drug discovery and development: Induced alveolar macrophage responses, Adv. Drug Deliv. 
Rev. 71 (2014) 15–33. doi:10.1016/j.addr.2014.02.001. 
[6] C. Loira-Pastoriza, J. Todoroff, R. Vanbever, Delivery strategies for sustained drug release in 
the lungs, Adv. Drug Deliv. Rev. 75 (2014) 81–91. doi:10.1016/j.addr.2014.05.017. 
[7] F. Lacoeuille, E. Garcion, J.-P. Benoit, A. Lamprecht, Lipid nanocapsules for intracellular drug 
delivery of anticancer drugs., J. Nanosci. Nanotechnol. 7 (2007) 4612–4617. 
doi:10.1166/jnn.2007.006. 
[8] N.T. Huynh, C. Passirani, P. Saulnier, J.P. Benoit, Lipid nanocapsules: A new platform for 
nanomedicine, Int. J. Pharm. 379 (2009) 201–209. doi:10.1016/j.ijpharm.2009.04.026. 
[9] J. Hureaux, F. Lagarce, F. Gagnadoux, L. Vecellio, A. Clavreul, E. Roger, et al., Lipid 
nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxel, Eur. J. 
Pharm. Biopharm. 73 (2009) 239–246. doi:10.1016/j.ejpb.2009.06.013. 
[10] E. Schultze, A. Ourique, V.C. Yurgel, K.R. Begnini, H. Thurow, P.M.M. De Leon, et al., 
Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to tretinoin, 
Eur. J. Pharm. Biopharm. 87 (2014) 55–63. doi:10.1016/j.ejpb.2014.02.003. 
[11] B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, J.P. Benoit, A novel phase inversion-based 
process for the preparation of lipid nanocarriers, Pharm. Res. 19 (2002) 875–880. 
doi:10.1023/A:1016121319668. 
[12] A. Kumar, L.A. Dailey, B. Forbes, Lost in translation: what is stopping inhaled nanomedicines 
from realizing their potential?, Ther. Deliv. 5 (2014) 757–761. doi:10.4155/tde.14.47. 
[13] A. Lamprecht, Y. Bouligand, J.P. Benoit, New lipid nanocapsules exhibit sustained release 
properties for amiodarone, J. Control. Release. 84 (2002) 59–68. doi:10.1016/S0168-
3659(02)00258-4. 
[14] M.M.A. Abdel-Mottaleb, D. Neumann, A. Lamprecht, In vitro drug release mechanism from 
lipid nanocapsules (LNC), Int. J. Pharm. 390 (2010) 208–213. 
doi:10.1016/j.ijpharm.2010.02.001. 
[15] M.C. Jones, S.A. Jones, Y. Riffo-Vasquez, D. Spina, E. Hoffman, A. Morgan, et al., 
Quantitative assessment of nanoparticle surface hydrophobicity and its influence on 
pulmonary biocompatibility, J. Control. Release. 183 (2014) 94–104. 
doi:10.1016/j.jconrel.2014.03.022. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
 
[16] L.A. Dailey, R. Hernández-Prieto, A.M. Casas-Ferreira, M.-C. Jones, Y. Riffo-Vasquez, E. 
Rodríguez-Gonzalo, et al., Adenosine monophosphate is elevated in the bronchoalveolar 
lavage fluid of mice with acute respiratory toxicity induced by nanoparticles with high 
surface hydrophobicity., Nanotoxicology. 5390 (2014) 1–10. 
doi:10.3109/17435390.2014.894150. 
[17] S. Hirsjärvi, S. Dufort, J. Gravier, I. Texier, Q. Yan, J. Bibette, et al., Influence of size, surface 
coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution 
of lipid nanocapsules versus lipid nanoemulsions in cancer models, Nanomedicine 
Nanotechnology, Biol. Med. 9 (2013) 375–387. doi:10.1016/j.nano.2012.08.005. 
[18] A. McElduff, L.E. Mather, P.C. Kam, P. Clauson, Influence of acute upper respiratory tract 
infection on the absorption of inhaled insulin using the AERx?? insulin Diabetes 
Management System, Br. J. Clin. Pharmacol. 59 (2005) 546–551. doi:10.1111/j.1365-
2125.2005.02366.x. 
[19] J.E. Gern, C.K. Stone, M. Nakano, D.B. Muchmore, A. de la Peña, S. Park, et al., Effect of 
upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and 
glucodynamics in healthy subjects., 2008. doi:10.1038/sj.clpt.6100286. 
[20] R.J. Szarka, N. Wang, L. Gordon, P.N. Nation, R.H. Smith, A murine model of pulmonary 
damage induced by lipopolysaccharide via intranasal instillation., J. Immunol. Methods. 202 
(1997) 49–57. 
[21] K.N. Kornerup, G.P. Salmon, S.C. Pitchford, W.L. Liu, C.P. Page, Circulating platelet-
neutrophil complexes are important for subsequent neutrophil activation and migration., J. 
Appl. Physiol. 109 (2010) 758–767. doi:10.1152/japplphysiol.01086.2009. 
[22] H.F. Håkansson, A. Smailagic, C. Brunmark, A. Miller-Larsson, H. Lal, Altered lung function 
relates to inflammation in an acute LPS mouse model, Pulm. Pharmacol. Ther. 25 (2012) 
399–406. doi:10.1016/j.pupt.2012.08.001. 
[23] Y. Riffo-Vasquez, F. Man, C.P. Page, Doxofylline, a novofylline inhibits lung inflammation 
induced by lipopolysacharide in the mouse, Pulm. Pharmacol. Ther. 27 (2014) 170–178. 
doi:10.1016/j.pupt.2014.01.001. 
[24] N. Mitchell, T.L. Kalber, M.S. Cooper, K. Sunassee, S.L. Chalker, K.P. Shaw, et al., 
Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes 
for multimodal imaging, Biomaterials. 34 (2013) 1179–1192. 
doi:10.1016/j.biomaterials.2012.09.070. 
[25] H.F. Lakatos, H. a Burgess, T.H. Thatcher, M.R. Redonnet, E. Hernady, J.P. Williams, et al., 
Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the 
mouse when compared to intratracheal instillation, Exp. Lung Res. 32 (2006) 181–199. 
doi:10.1080/01902140600817465. 
[26] C. Egger, C. Cannet, C. Gérard, E. Jarman, G. Jarai, A. Feige, et al., Administration of 
Bleomycin via the Oropharyngeal Aspiration Route Leads to Sustained Lung Fibrosis in Mice 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
 
and Rats as Quantified by UTE-MRI and Histology, PLoS One. 8 (2013) e63432. 
doi:10.1371/journal.pone.0063432. 
[27] M.A. Videira, M.F. Botelho, A.C. Santos, L.F. Gouveia, J.J.P. de Lima, A.J. Almeida, Lymphatic 
uptake of pulmonary delivered radiolabelled solid lipid nanoparticles., J. Drug Target. 10 
(2002) 607–613. doi:10.1080/1061186021000054933. 
[28] C.G. Tankersley, J. a Shank, S.E. Flanders, S.E. Soutiere, R. Rabold, W. Mitzner, et al., 
Changes in lung permeability and lung mechanics accompany homeostatic instability in 
senescent mice., J. Appl. Physiol. 95 (2003) 1681–1687. 
doi:10.1152/japplphysiol.00190.2003. 
[29] M. Semmler, J. Seitz, F. Erbe, P. Mayer, J. Heyder, G. Oberdörster, et al., Long-term 
clearance kinetics of inhaled ultrafine insoluble iridium particles from the rat lung, including 
transient translocation into secondary organs., Inhal. Toxicol. 16 (2004) 453–459. 
doi:10.1080/08958370490439650. 
[30] W.G. Kreyling, S. Hirn, W. Möller, C. Schleh, A. Wenk, G. Celik, et al., Air-blood barrier 
translocation of tracheally instilled gold nanoparticles inversely depends on particle size, 
ACS Nano. 8 (2014) 222–233. doi:10.1021/nn403256v. 
[31] S. Peltier, J.M. Oger, F. Lagarce, W. Couet, J.P. Benoît, Enhanced oral paclitaxel 
bioavailability after administration of paclitaxel-loaded lipid nanocapsules, Pharm. Res. 23 
(2006) 1243–1250. doi:10.1007/s11095-006-0022-2. 
[32] K.A. Shah, A.A. Date, M.D. Joshi, V.B. Patravale, Solid lipid nanoparticles (SLN) of tretinoin: 
Potential in topical delivery, Int. J. Pharm. 345 (2007) 163–171. 
doi:10.1016/j.ijpharm.2007.05.061. 
[33] P. Jain, G. Leitinger, R. Leber, C. Nagaraj, B. Lehofer, H. Olschewski, et al., Liposomal 
nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries, 
Int. J. Nanomedicine. (2014) 3249. doi:10.2147/IJN.S63190. 
[34] A. Woods, A. Patel, D. Spina, Y. Riffo-Vasquez, A. Babin-Morgan, R.T.M. de Rosales, et al., In 
vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug 
delivery, J. Control. Release. 210 (2015) 1–9. doi:10.1016/j.jconrel.2015.05.269. 
[35] B. Vaidya, V. Gupta, Novel therapeutic approaches for pulmonary arterial hypertension: 
Unique molecular targets to site-specific drug delivery., J. Control. Release. 211 (2015) 118–
133. doi:10.1016/j.jconrel.2015.05.287. 
[36] I.M. Rio-Echevarria, F. Selvestrel, D. Segat, G. Guarino, R. Tavano, V. Causin, et al., Highly 
PEGylated silica nanoparticles: ‘ready to use’ stealth functional nanocarriers, J. Mater. 
Chem. 20 (2010) 2780. doi:10.1039/b921735e. 
[37] J.L. Perry, K.G. Reuter, M.P. Kai, K.P. Herlihy, S.W. Jones, J.C. Luft, et al., PEGylated PRINT 
nanoparticles: The impact of PEG density on protein binding, macrophage association, 
biodistribution, and pharmacokinetics, Nano Lett. 12 (2012) 5304–5310. 
doi:10.1021/nl302638g. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
[38] S. Salmaso, P. Caliceti, Stealth properties to improve therapeutic efficacy of drug 
nanocarriers., J. Drug Deliv. 2013 (2013) 374252. doi:10.1155/2013/374252. 
[39] M. Semmler-Behnke, W.G. Kreyling, J. Lipka, S. Fertsch, A. Wenk, S. Takenaka, et al., 
Biodistribution of 1.4- and 18-nm gold particles in rats, Small. 4 (2008) 2108–2111. 
doi:10.1002/smll.200800922. 
[40] E. Roger, F. Lagarce, J.P. Benoit, The gastrointestinal stability of lipid nanocapsules, Int. J. 
Pharm. 379 (2009) 260–265. doi:10.1016/j.ijpharm.2009.05.069. 
[41] J. Chana, B. Forbes, S.A. Jones, Triggered-release nanocapsules for drug delivery to the 
lungs, Nanomedicine Nanotechnology, Biol. Med. 11 (2015) 89–97. 
doi:10.1016/j.nano.2014.07.012. 
[42] E. Roger, F. Lagarce, E. Garcion, J.P. Benoit, Lipid nanocarriers improve paclitaxel transport 
throughout human intestinal epithelial cells by using vesicle-mediated transcytosis, J. 
Control. Release. 140 (2009) 174–181. doi:10.1016/j.jconrel.2009.08.010.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
21 
 
 
